tiprankstipranks
Optimi Health Partners with Psyence Biomed for Psilocybin Trials
Company Announcements

Optimi Health Partners with Psyence Biomed for Psilocybin Trials

Story Highlights
  • Optimi Health supplies GMP-certified psilocybin for Psyence Biomed’s clinical trials.
  • The partnership supports Psyence Biomed’s Phase IIb trial and future commercialization.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Optimi Health (TSE:OPTI) has released an update.

Pick the best stocks and maximize your portfolio:

Optimi Health has partnered with Psyence Biomed to supply GMP-certified psilocybin for clinical trials aimed at addressing unmet mental health needs in palliative care. This collaboration not only supports Psyence Biomed’s current Phase IIb trial but also prepares for future Phase III studies and potential commercialization. The exclusive agreement ensures that Psyence Biomed will use Optimi’s psilocybin extract for its drug development and FDA registration efforts.

For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskOptimi Health’s MDMA Success in Australia
TipRanks Canadian Auto-Generated NewsdeskOptimi Health Advances Psilocybin Trial for Depression
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App